{"id":"placebo-of-levosimendan","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"As a placebo, this formulation is pharmacologically inert and is used in phase 3 trials to establish the efficacy and safety of the active levosimendan drug through blinded comparison. Levosimendan itself is a calcium sensitizer and vasodilator used in acute heart failure, but the placebo arm has no mechanistic activity.","oneSentence":"This is a placebo control arm and contains no active drug; it serves as a comparator in clinical trials of levosimendan.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:37.047Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Placebo control in phase 3 trials of levosimendan for acute decompensated heart failure"}]},"trialDetails":[{"nctId":"NCT07288398","phase":"PHASE3","title":"LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2","status":"RECRUITING","sponsor":"Tenax Therapeutics, Inc.","startDate":"2026-03-03","conditions":"Pulmonary Hypertension Associated With HFpEF","enrollment":540},{"nctId":"NCT05983250","phase":"PHASE3","title":"LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF","status":"RECRUITING","sponsor":"Tenax Therapeutics, Inc.","startDate":"2024-01-10","conditions":"Pulmonary Hypertension","enrollment":230},{"nctId":"NCT04158674","phase":"PHASE3","title":"Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2020-02-24","conditions":"Acute Decompensated Heart Failure","enrollment":82},{"nctId":"NCT07105202","phase":"PHASE4","title":"Shorter Weaning From Invasive Ventilation With Levosimendan","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2025-09-17","conditions":"Mechanical Ventilation, Weaning Failure","enrollment":250},{"nctId":"NCT05664191","phase":"PHASE2","title":"Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-10-13","conditions":"Sub-arachnoid Haemorrhage","enrollment":30},{"nctId":"NCT04020263","phase":"PHASE3","title":"Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock","status":"RECRUITING","sponsor":"Pr Bruno LEVY","startDate":"2023-07-03","conditions":"Cardiogenic Shock","enrollment":610},{"nctId":"NCT04705337","phase":"PHASE4","title":"Levosimendan In Ambulatory Heart Failure Patients","status":"TERMINATED","sponsor":"Medical University of Bialystok","startDate":"2021-12-15","conditions":"Heart Failure New York Heart Association Class III, Heart Failure New York Heart Association Class IV, Heart Failure, Systolic","enrollment":70},{"nctId":"NCT04329624","phase":"PHASE3","title":"Effect Levosimendan Administration on Postoperative NT-proBNP in Cardiac Risk Patients","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2020-10-10","conditions":"Cardiovascular Risk Factor","enrollment":230},{"nctId":"NCT04728932","phase":"PHASE3","title":"LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-08-27","conditions":"Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication","enrollment":206},{"nctId":"NCT03541603","phase":"PHASE2","title":"Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF","status":"COMPLETED","sponsor":"Tenax Therapeutics, Inc.","startDate":"2018-11-14","conditions":"Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction","enrollment":44},{"nctId":"NCT04330755","phase":"PHASE4","title":"Levosimendan Versus Combination With Magnesium Sulphate on Spine Protection by NIRS in Infants Undergoing Coarctectomy","status":"COMPLETED","sponsor":"Dalia Saad Abd-El Kader","startDate":"2021-02-04","conditions":"Aortic Coarctation","enrollment":40},{"nctId":"NCT05956431","phase":"PHASE4","title":"RCT Study of Levosimendan Improving Prognosis of Cardiac Arrest","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-08-01","conditions":"Heart Arrest","enrollment":60},{"nctId":"NCT05233202","phase":"PHASE3","title":"Levosimendan Versus Placebo Before Tricuspid Valve Surgery in Patients With Right Ventricular Dysfunction","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-01-23","conditions":"Patients Referred for an Isolated or a Combined Surgical Correction of Functional Moderate to Severe Tricuspid","enrollment":230},{"nctId":"NCT03022877","phase":"NA","title":"Acute and Chronic Protective Effects of Peri-interventional Administration of Levosimendan in ST Elevation Myocardial Infarctions","status":"WITHDRAWN","sponsor":"RWTH Aachen University","startDate":"2017-06","conditions":"Myocardial Infarction, Outcome","enrollment":""},{"nctId":"NCT03505021","phase":"PHASE3","title":"Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2018-06-21","conditions":"Amyotrophic Lateral Sclerosis","enrollment":496},{"nctId":"NCT04970238","phase":"PHASE4","title":"Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction","status":"UNKNOWN","sponsor":"Zhijun Sun","startDate":"2021-10","conditions":"ST Elevation Myocardial Infarction, Heart Failure","enrollment":500},{"nctId":"NCT02531724","phase":"PHASE4","title":"Effects of Levosimendan in Acute Kidney Injury After Cardiac Surgery","status":"COMPLETED","sponsor":"Sahlgrenska University Hospital","startDate":"2015-09","conditions":"Acute Kidney Injury, Renal Insufficiency, Acute","enrollment":30},{"nctId":"NCT03699215","phase":"PHASE3","title":"Clinical Trial in Patients Who Have Suffered a Heart Attack and Who Have Undergone Catheterization Treated With Levosimendan","status":"UNKNOWN","sponsor":"Hospital Universitario de Canarias","startDate":"2018-11-17","conditions":"ST Elevation Myocardial Infarction","enrollment":184},{"nctId":"NCT04573049","phase":"PHASE4","title":"The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2020-09-01","conditions":"Aortic Valve Stenosis, Heart Failure, Inotropic Agents","enrollment":124},{"nctId":"NCT04179604","phase":"PHASE2, PHASE3","title":"Spanish Randomized Clinical Trial to Compare Levosimendan Versus Placebo in Postoperative Cardiac Surgery (SPARTANS)","status":"UNKNOWN","sponsor":"María de los Ángeles Tena Pajuelo","startDate":"2020-06-17","conditions":"Cardiac Output, Low","enrollment":300},{"nctId":"NCT01500785","phase":"PHASE4","title":"Intracoronary Administration of Levosimendan in Cardiac Surgery Patients","status":"TERMINATED","sponsor":"Tampere University Hospital","startDate":"2018-06-15","conditions":"Myocardial Stunning","enrollment":50},{"nctId":"NCT03576677","phase":"PHASE4","title":"Effect of Levosimendan or Placebo on Exercise in Advanced Chronic Heart Failure","status":"UNKNOWN","sponsor":"Finn Gustafsson","startDate":"2019-08-01","conditions":"Heart Failure","enrollment":42},{"nctId":"NCT01318460","phase":"PHASE4","title":"Prophylactic Administration of Levosimendan in Patients Undergoing Coronary Surgery","status":"COMPLETED","sponsor":"AHEPA University Hospital","startDate":"2011-03","conditions":"Coronary Artery Disease","enrollment":32},{"nctId":"NCT01188369","phase":"PHASE4","title":"Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy","status":"TERMINATED","sponsor":"University of Aarhus","startDate":"2010-09","conditions":"Diastolic Dysfunction, Left Ventricular Hypertrophy","enrollment":20},{"nctId":"NCT03437226","phase":"PHASE3","title":"Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure","status":"UNKNOWN","sponsor":"Dr. Gerhard Pölzl","startDate":"2018-03-08","conditions":"Heart Failure","enrollment":264},{"nctId":"NCT02025621","phase":"PHASE3","title":"Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Tenax Therapeutics, Inc.","startDate":"2014-07","conditions":"Coronary Artery Bypass Grafting, Mitral Valve Surgery, Low Cardiac Output Syndrome","enrollment":882},{"nctId":"NCT02487407","phase":"PHASE2","title":"Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2015-07","conditions":"Amyotrophic Lateral Sclerosis","enrollment":66},{"nctId":"NCT01720030","phase":"PHASE2, PHASE3","title":"Levosimendan in Acute Kidney Injury Study","status":"UNKNOWN","sponsor":"VieCuri Medical Centre","startDate":"2016-09","conditions":"Acute Kidney Injury","enrollment":68},{"nctId":"NCT00994825","phase":"PHASE4","title":"Levosimendan in High Risk Patients Undergoing Cardiac Surgery","status":"COMPLETED","sponsor":"Università Vita-Salute San Raffaele","startDate":"2009-11","conditions":"Low Cardiac Output Syndrome","enrollment":1000},{"nctId":"NCT02184819","phase":"PHASE3","title":"Preoperative Levosimendan in CABG Patients With Poor LV Function","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-06","conditions":"Coronary Artery Bypass Grafting, Left Ventricular Dysfonction","enrollment":335},{"nctId":"NCT01536132","phase":"PHASE4","title":"Intermittent Intravenous Levosimendan in Ambulatory Advanced Chronic Heart Failure Patients","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2010-04","conditions":"Heart Failure","enrollment":70},{"nctId":"NCT02261948","phase":"PHASE4","title":"Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET)","status":"COMPLETED","sponsor":"Centro Cardiologico Monzino","startDate":"2012-09","conditions":"Heart Failure","enrollment":42},{"nctId":"NCT01721434","phase":"PHASE2, PHASE3","title":"Effects of Levosimendan on Diaphragm Function in Mechanically Ventilated Patients","status":"UNKNOWN","sponsor":"University Medical Center Nijmegen","startDate":"2012-09","conditions":"Muscle Weakness Conditions, Weaning Failure","enrollment":42},{"nctId":"NCT01595737","phase":"PHASE4","title":"Comparison of the Administration of Levosimendan and Placebo in the Preparation of Critical Patients for Heart Surgery","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2011-02","conditions":"Cardiac Surgery","enrollment":30},{"nctId":"NCT00988806","phase":"PHASE4","title":"Long-Term Intermittent Administration of Levosimendan in Patients With Advanced Heart Failure","status":"UNKNOWN","sponsor":"Hospital Universitario de Canarias","startDate":"2009-11","conditions":"Advanced Heart Failure","enrollment":213},{"nctId":"NCT01022983","phase":"PHASE4","title":"Preoperative Levosimendan and Heart Failure","status":"WITHDRAWN","sponsor":"Sykehuset i Vestfold HF","startDate":"2011-04","conditions":"Heart Failure, Hip Fracture","enrollment":""},{"nctId":"NCT01120106","phase":"PHASE2","title":"Levosimendan Administration in Neonates With Transposition of the Great Arteries","status":"COMPLETED","sponsor":"Bambino Gesù Hospital and Research Institute","startDate":"2009-01","conditions":"Low Cardiac Output Syndrome","enrollment":63},{"nctId":"NCT00324766","phase":"PHASE4","title":"Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction.","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2006-06","conditions":"Myocardial Infarction, Heart Failure, Cardiogenic Shock","enrollment":61},{"nctId":"NCT01210976","phase":"PHASE4","title":"The Effects of Levosimendan on Haemodynamics in Patients Undergoing Elective Aortic Valve Replacement (AVR)Together With Coronary Artery Bypass Grafting (CABG) Surgery","status":"COMPLETED","sponsor":"Tampere University Hospital","startDate":"2009-01","conditions":"Heart Valve Disease","enrollment":24},{"nctId":"NCT01101620","phase":"NA","title":"Effect of Levosimendan on Respiratory Muscle Function in Healthy Subjects","status":"COMPLETED","sponsor":"University Medical Center Nijmegen","startDate":"2010-04","conditions":"Respiratory Muscle Function","enrollment":30},{"nctId":"NCT01221116","phase":"NA","title":"Inotropic Treatment With Levosimendan (SimdaxR)in Heart Surgery","status":"TERMINATED","sponsor":"Ullevaal University Hospital","startDate":"2003-01","conditions":"Heart Failure, Cardiac Surgery","enrollment":23},{"nctId":"NCT01065194","phase":"PHASE3","title":"Efficacy and Safety of Pulsed Infusions of Levosimendan in Outpatients With Advanced Heart Failure","status":"UNKNOWN","sponsor":"Medical University Innsbruck","startDate":"2009-08","conditions":"Chronic Stable Heart Failure","enrollment":120},{"nctId":"NCT00698763","phase":"PHASE2","title":"Effects of Oral Levosimendan on Ambulatory Electrocardiographic Variables","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2008-08","conditions":"Transient Ischemic Attack, Stroke","enrollment":32},{"nctId":"NCT00154115","phase":"PHASE4","title":"Levosimendan in High Risk Heart Valve Surgery","status":"COMPLETED","sponsor":"Kuopio University Hospital","startDate":"2005-03","conditions":"Heart Failure","enrollment":200},{"nctId":"NCT00610350","phase":"PHASE4","title":"Levosimendan and Myocardial Protection","status":"COMPLETED","sponsor":"University of Roma La Sapienza","startDate":"2005-01","conditions":"Myocardial Protection","enrollment":100},{"nctId":"NCT00130884","phase":"PHASE2","title":"Peroral Levosimendan in Chronic Heart Failure","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2005-03","conditions":"Chronic Heart Failure, Heart Diseases","enrollment":300},{"nctId":"NCT00048425","phase":"PHASE3","title":"Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-09","conditions":"Heart Failure, Congestive","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":240,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo of Levosimendan","genericName":"Placebo of Levosimendan","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control arm and contains no active drug; it serves as a comparator in clinical trials of levosimendan. Used for Placebo control in phase 3 trials of levosimendan for acute decompensated heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}